Accelerating Medicines Partnership® SCHIZOPHRENIA
For Scientists
Using data from a non-interventional study, the Accelerating Medicines Partnership (AMP®) SCZ program seeks to build tools to improve success in developing pharmacologic treatments for patients with clinical high risk for psychosis.

Data Sharing


An important component of the Accelerating Medicines Partnership (AMP®) SCZ program is the rapid dissemination of research data and analysis pipelines to the research community.

The AMP SCZ program data are available to the larger research community for further study on the National Institute of Mental Health (NIMH) Data Archive (NDA). All AMP SCZ program data stored in the NDA adheres to the NDA terms and conditions and the NIMH Data Sharing Policy. Specifically, participant data are aggregated in a privacy-enabled manner and are protected by practices that include the removal of any personal identifiable information; accredited users are given secure, role-based access to the data.

November 2023 Update: The AMP SCZ Data Release 1.0 is available (DOI: 10.15154/18rd-ck75).This data release contains fully quality-controlled screening and baseline data from 430 unique subjects ages 12-30. These include curated and tabulated behavioral and clinical measures, electroencephalography and imaging data (plain text, comma-separated values files) and associated data. Learn more about what data is available and how researchers with an approved NDA Data Use Certification may obtain it.

Please note that this first AMP SCZ data release provides baseline data for a relatively small subset of clinical high-risk (CHR) and healthy control participants. The initial data release allows users to view the quality and multiple data types that are, and will be, available. Researchers are encouraged to test hypotheses related to biomarkers for CHR after data collection across the cohort of study participants is complete.


Last Reviewed on December 2, 2023